Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Power Hour is about to start! i predict a close at.......

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Apr 14, 2020 4:20pm

119 Views

Post# 30908954

RE:RE:RE:RE:Power Hour is about to start! i predict a close at.......

craiggers83 wrote: Is that your only basis for linking KLY to a COVID treatment? Does anyone have a real reason to suggest KLY would suddenly begin developping a treatment for COVID. I am pretty sure what is needed is a vaccine, not anti-inflamatory drug.

KLY already has huge potential. We'll reap the rewards from the projects they already have in motion.

Yes - we need vaccine - but a full development of one would take ... how long? What about during the meantime?

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles